5. Effects of stopping smoking
at various ages on the
cumulative risk (%) of death
from lung cancer up to age
75, at death rates for men in
UK in 1990. Nonsmoker
rates were taken from US
prospective study of
mortality
Peto R, BMJ, 2000
8. MMaayyoo LLuunngg CCaanncceerr SSccrreeeenniinngg PPrroojjeecctt
9 2 1 1 S t u d y P a r t i c i p a n t s
S c r e e n e d G r o u p
C X R & p o o l e d s p u t u m
q 4 m o n t h s
L u n g C a n c e r s = 2 0 6
S t a g e I & I I ( r e s e c t e d ) 8 3 ( 4 0 % )
L a t e - s t a g e ( u n r e s e c t e d ) 1 2 3 ( 6 0 % )
S t a n d a r d c a r e r e c o m m e n d a t i o n
a t s t u d y e n t r y
L u n g C a n c e r s = 1 6 0
S t a g e I & I I ( r e s e c t e d ) 4 1 ( 2 5 % )
L a t e - s t a g e ( u n r e s e c t e d ) 1 1 9 ( 7 5 % )
Marcus, JNCI, 2000
28. Diagnostic Pathways for CT Nodules 4-10 mm
Low Dose
Thin Section
Nodule CT
at 4-6 Months1,2
Solid or
Mixed Nodule
4-10 mm
on Baseline
Screening CT
No Growth3
or
Resolution
Growth but
< 7 mm
Diameter
Growth
> 7 mm
Diameter
Continue Annual
Screen
Repeat Low Dose
TSCT at 3 to 6 Months
[or Abnormal Pathways]
ABNORMAL
Nodule Pathways
1 Pure ground glass nodules can be followed-up at 6-12 months if < 10 mm.
2 Some nodules 4-10 mm may go directly to biopsy or other tests in ABNORMAL pathways.
3 No growth is defined as < 15% increase in overall diameter OR no ↑ in solid component.
29. ABNORMAL Pathways: Nodules >10 mm
Solid,
Mixed or
GG Nodule
>10 mm
Biopsy: Percutaneous, Bronchoscopic, Thoracoscopic, Open
DCE-CT
FDG-PET
Enhance <15 HU
Enhance ³15 HU
1 Reserved for nodules considered highly likely to be BENIGN
[polygonal shape, 3D shape ratio > 1.78]
Biopsy -OR-Definitive
Management
No Activity
Low Dose TSCT
at 3-4 Months1 Per Protocol
TSCT at
6 -12 months
TSCT at
6 -12 months
Activity